Sean  Werner net worth and biography

Sean Werner Biography and Net Worth

Chief Technology Officer of BioLife Solutions

BS Biology, PhD, Biology with post-doctoral positions at the Indiana University School of Medicine and Eli Lilly; 23 years in the life science industry, guiding regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools. Experienced in various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs.

What is Sean Werner's net worth?

The estimated net worth of Sean Werner is at least $111,145.32 as of March 3rd, 2025. Dr. Werner owns 4,953 shares of BioLife Solutions stock worth more than $111,145 as of April 4th. This net worth evaluation does not reflect any other investments that Dr. Werner may own. Learn More about Sean Werner's net worth.

How do I contact Sean Werner?

The corporate mailing address for Dr. Werner and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at rdegreef@biolifesolutions.com. Learn More on Sean Werner's contact information.

Has Sean Werner been buying or selling shares of BioLife Solutions?

Sean Werner has not been actively trading shares of BioLife Solutions during the last quarter. Most recently, Sean Werner sold 136 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $25.46, for a transaction totalling $3,462.56. Following the completion of the sale, the chief technology officer now directly owns 4,953 shares of the company's stock, valued at $126,103.38. Learn More on Sean Werner's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Amy Duross (Director), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Geraint Phillips (SVP), Michael Rice (CEO), Garrie Richardson (CRO), Joseph Schick (Director), Marcus Schulz (CRO), Sean Werner (Chief Technology Officer), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, insiders at the medical equipment provider sold shares 71 times. They sold a total of 228,010 shares worth more than $5,128,781.07. The most recent insider tranaction occured on April, 1st when insider Sarah Aebersold sold 5,771 shares worth more than $130,770.86. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 4/1/2025.

Sean Werner Insider Trading History at BioLife Solutions

See Full Table

Sean Werner Buying and Selling Activity at BioLife Solutions

This chart shows Sean Werner's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$2k$0$2kTotal Insider BuyingTotal Insider Selling

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $20.87
Low: $20.07
High: $22.31

50 Day Range

MA: $26.00
Low: $22.44
High: $28.49

2 Week Range

Now: $20.87
Low: $14.84
High: $29.55

Volume

612,492 shs

Average Volume

331,573 shs

Market Capitalization

$980.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04